Insulin Glulisine
Metabolic / DiabetesAlso known as: Apidra, Apidra SoloStar, Sanofi Rapid Insulin
Mechanism
Insulin Glulisine (brand name Apidra) is a rapid-acting insulin analog designed to mimic the body's natural mealtime insulin spike. It starts working within 15 minutes of injection and peaks at about 1 hour — much faster than regular human insulin. This makes it ideal for controlling blood sugar spikes after meals. It was engineered by swapping two amino acids in human insulin to prevent the molecules from clumping together, allowing faster absorption from the injection site.
Technical detail
Insulin glulisine is a rapid-acting recombinant insulin analog with two amino acid modifications vs. human insulin: AsnB3→Lys and LysB29→Glu. These substitutions disrupt the zinc-mediated hexamer formation that slows absorption of regular insulin. At physiological concentrations, glulisine exists primarily as monomers/dimers rather than hexamers, enabling rapid absorption from SubQ depot. Pharmacokinetics: onset 10-15 minutes, peak 30-90 minutes, duration 3-5 hours (vs. regular insulin: onset 30 min, peak 2-4 h, duration 6-8 h). Once absorbed, binds the insulin receptor (IR-A and IR-B isoforms) with affinity equivalent to human insulin. Activates canonical insulin signaling: IR autophosphorylation → IRS-1/2 → PI3K → Akt → GLUT4 translocation (glucose uptake) and glycogen synthase activation. Also suppresses hepatic glucose output and inhibits lipolysis. IGF-1R binding affinity similar to human insulin (no increased mitogenicity concerns).